Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Receivables: 2010-2025

Historic Change in Receivables for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $34.2 million.

  • Ironwood Pharmaceuticals' Change in Receivables rose 88.96% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 191.35%. This contributed to the annual value of -$47.2 million for FY2024, which is 5012.12% down from last year.
  • Ironwood Pharmaceuticals' Change in Receivables amounted to $34.2 million in Q3 2025, which was down 26.31% from $46.4 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Change in Receivables ranged from a high of $46.4 million in Q2 2025 and a low of -$57.1 million during Q1 2024.
  • For the 3-year period, Ironwood Pharmaceuticals' Change in Receivables averaged around -$880,455, with its median value being $4.6 million (2023).
  • In the last 5 years, Ironwood Pharmaceuticals' Change in Receivables soared by 4,405.71% in 2022 and then slumped by 529.13% in 2024.
  • Ironwood Pharmaceuticals' Change in Receivables (Quarterly) stood at $12.4 million in 2021, then plummeted by 107.55% to -$937,000 in 2022, then skyrocketed by 588.47% to $4.6 million in 2023, then rose by 24.19% to $5.7 million in 2024, then soared by 88.96% to $34.2 million in 2025.
  • Its last three reported values are $34.2 million in Q3 2025, $46.4 million for Q2 2025, and -$42.1 million during Q1 2025.